Menu

Geneticist Announces Congressional Bid

UC Berkeley researcher Michael Eisen says he will run for Senate in 2018.

Jan 30, 2017
Bob Grant

WIKIMEDIA, PLOSGeneticist Michael Eisen of the University of California, Berkeley, has been a vocal opponent of Donald Trump. Now, the researcher has announced his intent to run for US Senate. “We can't sit around and hope other people are going to solve our problems for us - time to step up, if you can…,” Eisen posted on his Twitter account on Sunday (January 29) after announcing his senate run last week (January 25).

“Too much of the scientific establishment looks at the government as a bank—that the primary thing we should worry about is can we get the right amount of money out of Congress,” Eisen told Science. “Too few people focus on the fact that science needs to be a partnership with the public for it to thrive.”

Eisen, who told Science that he plans to run as an independent, is perhaps the most recognizable name in a list of other scientists who are considering running for office to combat policies that seem broadly antagonistic to science. The groundswell is partly thanks to 314 Action, an organization run by chemist and former breast cancer researcher Shaughnessy Naughton, who ran for Congress in 2014 and 2016 but lost both races. Through 314 Action, Naughton and others are encouraging scientists to run for office and inject science into the federal political infrastructure. “A lot of scientists traditionally feel that science is above politics but we’re seeing that politics is not above getting involved in science,” Naughton told The Atlantic. “We’re losing, and the only way to stop that is to get more people with scientific backgrounds at the table.”

Donald Trump assuming the presidency earlier this month seems to have catalyzed scientists, not just into marching in protest against the new administration's science policies, but into running for office. “I think most scientists view their work as pure and noble, and politics as a dirty game. It’s almost like selling out or going to the dark side,” Frances Colón, who was Deputy Science and Technology Adviser to the Secretary of State under President Barack Obama, told The Atlantic. “Many more scientists are realizing why their voices are needed. I’ve had numerous coffees with people who are considering ways to run.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.